Numerous randomized controlled studies assessing intracoronary bone marrow cell therapy (BMC) after acute myocardial infarction (AMI) have been performed.
ASBTRACT Context
Numerous randomized controlled studies assessing intracoronary bone marrow cell therapy (BMC) after acute myocardial infarction (AMI) have been performed.
Objective
To systematically review the effect of autologous BMC therapy on left ventricular function by performing an up to date meta-analysis of randomized controlled trials (RCTs) including long-term follow-up.
Data sources
Trials were identified through a literature search from 1980 to June 2012 of the Pubmed, Embase, Cochrane database, and the Current Controlled Trials Register.
Study selection
Randomized clinical trials comparing intracoronary BMC infusion to control as treatment for AMI.
Data extraction
The primary endpoint was the change in left ventricular ejection fraction (LVEF) from baseline to follow-up. Secondary endpoints were changes in left ventricular end diastolic volume (LVEDV), left ventricular end systolic volume (LVESV), infarct size and clinical outcomes.
Results
Improvement of LVEF in patients receiving intracoronary BMC was significantly better within 6 months (23 studies, 2.23% [95% confidence interval (CI) 1.00 to 3.47]; p < 0.001). At 12 months of follow-up, this effect sustained with 3.91% more LVEF improvement (11 studies, [95% CI 2.56 to 5.27], p <0.001). At long-term follow-up, we found a trend for better LVEF improvement in favor of cell therapy (7 studies, 1.90% [95% CI -0.43 to 4.23]; p=0.11). There was no clear effect in infarct size or LVEDV. However, we found a significant reduction in LVESV at 6 months (-4.81 ml [95% CI -7.86 to -1.76]; p<0.001 and at 12 months (-9.41 ml [95% CI -13.64 to -5.17]; p<0.001). Moreover, there was a statistically significant decrease in recurrent AMI (Relative Risk (RR) 0.44 [95% CI 0.24 to 0.79]; p =0.007), and readmission for heart failure, unstable angina or chest pain (RR 0.59 [95% CI 0.35 to 0.98]; p = 0.04) in favor of cell therapy.
Conclusion
Intracoronary BMC treatment leads to a moderate improvement of LVEF and reduction of LVESV at 6 months that sustained at 12 months follow-up, without a clear significant effect on LVEDV, or infarct size. Furthermore, we found that intracoronary cell therapy is significantly associated with a reduction in recurrent AMI and readmission for heart failure, unstable angina or chest pain.
INTRODUCTION
Despite optimal state-of-the-art medical and revascularization therapies, the progression and development of congestive heart failure is still considered a large burden.
1 Acute myocardial infarction (AMI) is a major cause of congestive heart failure. 2 Therefore, alternative therapies to complement primary percutaneous coronary intervention (PCI) or thrombolytic therapy in the prevention of congestive heart failure after acute myocardial infarction are being investigated.
One of the suggested therapies for myocardial dysfunction is intracoronary bone marrow cell (BMC) treatment, which was tested positive in several animal studies. From then on, clinical trials rapidly followed to translate these exciting preclinical results to humans. 3 Numerous relatively small randomized controlled studies with different types of cells, different dosages, and follow-up durations were performed. The effect of cell therapy in AMI patients has been reviewed in de past, [37] [38] [39] [40] showing a small significant effect after myocardial infarction of left ventricular ejection fraction (LVEF) and other endpoints as left ventricular end diastolic volume (LVEDV), left ventricular end systolic volume (LVESV), and infarct size. However, these reviews did not include latest studies and follow-up. Our aim was to systematic review the effect of intracoronary injection of autologous bone marrow cell (BMC) after AMI by performing an up to date meta-analysis of randomized controlled trials (RCTs).
METHODS literature search and study selection
We identified all published trials comparing intracoronary infusion of BMC as treatment for AMI to control by searching Pubmed, Embase, Cochrane database and the Current Controlled Trials Register from 1980 to 1 st June 2012. The following key words were used: "bone marrow cells," "stem cell", "bone marrow transplantation", "precursor cell", "progenitor cell", "haemopoietic marrow", "myocardial ischemia", "ischemia", "ischemic heart disease", "coronary heart disease", "heart failure", "cardiac", "cardiomyo", "ischemia" (see appendix 1). Additionally, we manually searched the conference abstracts of the American Heart Association, American College of Cardiology, European Society of Cardiology and Transcatheter Cardiovascular Therapeutics, KoreaMed, IndMed and LILACS. We also searched the references of identified studies and relevant review articles to identity additional randomized studies.
To be included, trials had to: be randomized; include patients with a clinical diagnosis of acute AMI, treated with PCI; and compare a single intracoronary infusion of autologous BMC (irrespective of the type and number of isolated cells) within one month of AMI to a comparator arm not receiving BMC (e.g. control media or plasma or standard treatment). We did not include trials where follow-up was less than 3 months or granulocyte (macrophage) colony-stimulating factor (G(M)-CSF) was administrated as co-intervention. Study selection was done by two independent reviewers (RD, AA) and disagreement was resolved by a third reviewer (AH).
Data extraction and data analysis
Data from the original publications, including markers of validity, study design, nature of the intervention, and clinical and imaging outcomes were obtained from the original publications.
The primary endpoint was the change in LVEF from baseline to follow-up. Secondary endpoints were changes in LVESV, LVEDV, infarct size and clinical outcomes (all cause mortality, recurrent AMI, target vessel revascularization and readmission for heart failure, unstable angina or chest pain). Per endpoint we involved only those studies in the analysis for which the information about the endpoint had been published. The quantitative information about endpoint per treatment group was obtained by extracting the mean change ± SD from the publication.
When several methods were used for outcome assessment, magnetic resonance imaging (MRI) data were preferentially included in the analysis, followed by single photon emission computed tomography (SPECT), echocardiography, and left ventricular (LV) angiography. LVESV and LVEDV were collected in ml/m² or ml when ml/m² was not available. Infarct size was preferable collected in % of LV or grams when not available. When reported or published data were incomplete, we requested additional details by correspondence, generally with the principal investigator, searched previously published Cochrane reviews, or calculated or estimated these data using the method of the Cochrane handbook. 41 If trials consisted of multiple intervention comparator arms, we only used data from the comparator arm meeting the in-and exclusion criteria. If the multiple interventions arms all were eligible, we used the combined data if available and if not available we separated them into different studies.
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Statistical analysis
Outcomes were analyzed with random-effects models. Summary results were presented as weighted mean difference (WMD) with 95% confidence interval per imaging outcome. We presented imaging outcomes split for different follow-up duration (3-6 months, 12 months and > 12 months) and different units used (ml/m² versus ml and %/LV versus grams)
We examined heterogeneity across studies by calculating an I²-value for every outcome. A standard fixed effects model (Mantel-Haenszel method) was used in the absence of heterogeneity among studies (I² value less than 50%). In the presence of heterogeneity the DerSimonian and Laird random effects model was used. Funnel plots were plotted to investigate possible publication bias. Analysis were performed using RevMan 4.2 (The Cochrane Collaboration, Copenhagen, Denmark), with statistical significance for hypothesis testing set at the 0.05, 2-tailed level.
RESUlTS
From the initial 2124 citations (Figure 1 ), 2025 citations were initially excluded at the title/abstract level. Fifty-four of the remaining 99 citations were RCTs, of which 24 studies were eligible for inclusion. These trials allocated 1624 patients to intracoronary cell therapy or standard therapy, ranging from 10 to 204 participants per trial. Table  1 . Ten studies included patients with anterior myocardial infarction only. Only 7 studies were double blinded and 12 studies used MRI as diagnostic modality. Follow-up ranged from 3 to 60 months. Twenty studies used mononuclear bone marrow cells for infusion (Table 2) . Most trials fulfilled our markers of validity (Table 3) .
Change in lVEF
The change in LVEF within 6 months was available in 23 studies (Figure 2) . Improvement of LVEF within 6 months in patients receiving intracoronary cell therapy was significantly augmented compared to standard therapy (2.23% [95% confidence interval (CI) 1.00 to 3.47]; p < 0.001). At 12 months of follow-up, this effect sustained with 3.91% more LVEF improvement (eleven studies, [95% CI 2.56 to 5.27], p <0.001) in patients receiving intracoronary cell therapy. At long term follow-up, we found a trend for better LVEF improvement in favor of cell therapy (seven studies, 1.90% [95% CI -0.43 to 4.23]; p=0.11), although the number of studies was small. Assessment of publication bias using visual examination of the funnel plot of the primary publications indicated no significant publication bias (Figure 3 (Figure 4 ). However, we found a significant reduction in LVESV at 6 months (-4.81 ml [95% CI -7.86 to -1.76]; p<0.001 and -0.55 ml/m² [95% CI -2.57 to 1.47]; p=0.59), at 12 months ( -9.41 ml [95% CI -13.64 to -5.17]; p<0.001) and at long-term follow-up (-5.53 ml [95% CI -10.97 to -0.08]; p=0.05) in patients receiving intracoronary cell therapy (Appendix 2). There were only 2 studies reporting on LVEDV and LVESV in ml/m² on longer term showing no benefit of cell therapy. There was a trend towards infarct size reduction in patients receiving intracoronary cell therapy at 6 months (-2.16 gram [95% CI -4.45 to 0.14], p=0.07) (Appendix 3). However, in the studies where infarct size was reported in % of LV, the difference was 0.01% ([95% CI, -1.38 to 1.40], p=0.99). Infarct size in grams or % of LV was reported in 9 of the 24 studies. Table 4 . 
DISCUSSION
In the present meta-analysis, we found that BMC treatment leads to a slightly better improvement of LVEF and reduction of LVESV at 6 months, which was sustained at 12 months follow-up, without a clear significant effect on LVEDV or infarct size. Furthermore, we found that intracoronary cell therapy is significantly associated with a reduction in recurrent AMI, and readmission for heart failure, unstable angina or chest pain.
In the past years, earlier reports have presented a meta-analysis regarding BMC cell therapy after MI.(37-40) Our meta-analysis differs from previously published metaanalysis. First, other meta-analysis also included studies that administered G(M)-CSF or bone marrow derived cells from the peripheral blood group and/or included both acute and chronic myocardial infarction patients making the results more heterogeneous. Second, all meta-analyses pooled different outcome measures for LVEDV, LVESV, and infarct size used in the trials. We have chosen to present these outcomes separately, because this is more precise. Third, our meta-analysis is more up to date containing a larger number of studies and latest follow-up. However, our results are globally in agreement with the results of the previous meta-analyses, namely that cell therapy results in a slightly better significant improvement of LVEF compared to controls, without a clear significant effect on LVEDV or infarct size.
There has been a lot of controversy regarding high risk subgroups benefitting more from cell therapy, appropriate cell storage, cell dosage and cell type. Unfortunately this metaanalysis does not answer these relevant questions but bundles all trials with a high degree of heterogeneity.
Finally the question remains whether a small increase of LVEF is clinically meaningful. However as Reffelman et al. stated when putting the moderate increases of cardiac volumes in perspective with existing therapy, we appear to be in the range of effects observed with reperfusion therapy, pharmacotherapeutic interventions influencing the renin-angiotensin-aldosterone pathway, and beta-blockers after AMI. 42 More importantly, we found that intracoronary cell therapy is associated with a significant reduction in recurrent AMI and readmission for heart failure, unstable angina or chest pain. The mechanism behind these significant reductions remains unclear and could be biased due to the low number of clinical events or placebo effect (in case of readmission for heart failure, unstable angina or chest pain). It has been suggested that BMC therapy alters the process of restenosis development and/or atherosclerotic disease progression via enhanced reendothelialization and potential vascular repair. Also, it has been hypothesized that BMC leads to greater recovery of coronary blood flow reserve which is inversely associated with atherosclerotic disease progression, which may in turn explains the lower rate of recurrent MI. 24 However, these hypotheses are highly speculative and should further be investigated.
We feel that intracoronary bone marrow cell treatment still holds promise and should be investigated in a large clinical trial with clinical outcomes as primary endpoint. The large BAMI trial, funded by the European Union, will investigate BMC therapy in a RCT with a primary clinical endpoint." This meta-analysis shows that there is little space for more small randomized controlled trial assessing intracoronary BMCs in acute myocardial infarction with surrogate primary endpoints.
CONClUSION
Intracoronary bone marrow cell treatment leads to a moderate improvement of LVEF and reduction of LVESV at 6 months, that sustained at 12 months follow-up, without a clear significant effect on LVEDV, or infarct size. Furthermore, we found that intracoronary cell therapy is significantly associated with a reduction in recurrent AMI and readmission for heart failure, unstable angina or chest pain.
